

29th December, 2021

The Dy. General Manager (Listing Dept.)
BSE Limited.,
Corporate Relationship Dept.,
1st Floor, New Trading Ring,
P. J. Towers, Dalal Street, Fort,
Mumbai - 400 001
(BSE Scrip Code: 500420)

The Manager – Listing Dept.,
National Stock Exchange of India Ltd.,
Exchange Plaza, 5th Floor,
Plot No. C/1, G. Block,
Bandra - Kurla Complex, Bandra (E),
Mumbai – 400 051
(NSE Scrip Code: TORNTPHARM)

Dear Sir

Subject : Clarification on News Item

Ref : Your email dated 28th December 2021 seeking clarification on recent news in Money Control dated 27th December 2021.

With reference to the above on the news captioned “Torrent Pharma recalls over 27000 bottles of blood pressure lower drug in US”, our responses are as follows:

a) *Whether such negotiations/events were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order from the start of negotiations/events till date*

Response: The Company has voluntarily recalled one batch of Telmisartan and Hydrochlorothiazide Tablets 40 / 12.5 mg from the US market to the retail level on 1st December 2021. The drug has been recalled due to out of specification assay result found during the routine testing of the batch.

b) *Whether you/company are aware of any information that has not been announced to the Exchanges which could explain the movement in the trading, if any? Further, you are advised to provide the said information and the reasons for not disclosing the same to the Exchange earlier as required under regulation 30 of the SEBI (LODR) Regulations, 2015.*


Response : No

c) *The material impact of this article on the Company*

Response : There is no material impact of this article on the Company

Should you require further clarification, kindly let us know.

For TORRENT PHARMACEUTICALS LIMITED



MAHESH AGRAWAL
VP (LEGAL) & COMPANY SECRETARY

